Over the past three years the number of partnerships being inked between drug developers and diagnostics companies has soared, according to PricewaterhouseCoopers.
AstraZeneca's decision to expand its diabetes partnership with Bristol-Myers Squibb in the wake of the $5.3 billion Amylin buyout is the biggest new deal in a string of drug pacts completed this year. But don't expect the pharma giant to back away from the deal table anytime soon.
About a year-and-a-half ago Avalon Ventures' founder Kevin Kinsella caused a stir when he attacked pharma companies for their "predatory" deals with biotech companies. Now the San Diego-based investor is back, offering his hometown newspaper some highly quotable views on biotech investing, the personalized medicine trend, the futility of gene sequencing and more.
Paul Beresford, vice president of business development and strategic marketing at Biodesix, spoke to FierceBiomarkers ahead of his appearance on the BIO2012 panel "Commercialization of Personalized Medicine: Stakeholders' Recipe For Success." So what is Biodesix's own recipe for success? Keeping it collaborative and seeking validation, he explains.
Silicon Valley Biosystems has emerged from top-secret status this week with bold plans to provide doctors with high-quality reports on their patients' genomes, challenging a growing crowd of software companies with similar goals, Bio-IT World 's veteran editor Kevin Davies reported.
GenomOncology has jumped into the race to analyze genetic data for cancer specialists. With applications in pharma and research labs and oncology clinics, the company's "genomic-analysis-as-service" plan has attracted a $250,000 commitment from the nonprofit venture group JumpStart.
Agendia has pulled in $65 million in a private round of equity financing, with plans to use the massive cash infusion to advance and expand commercial development of its cancer-focused molecular diagnostic tests.
The FoundationOne molecular diagnostic test is a unique mix of genetic sequencing and data gathering designed to help oncologists pick the best treatment for individual patients.
Swiss drug giant Roche ($RHHBY) has renewed a license to Genedata's software for managing omics data to explore molecular pathways and validate biomarkers.
Studies give boost to Genentech/Roche's ($RHHBY) Avastin (bevacizumab) and Amgen's ($AMGN) rilotumumab.